Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain-Scan AI could spot Parkinson's without costly PET imaging

NCT ID NCT04334902

Diagnosis Sponsor: Heuron Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested a software called mPDia that uses MRI brain scans to help doctors diagnose neurodegenerative parkinsonism, a group of movement disorders including Parkinson's disease. The study involved 221 adults and compared mPDia's accuracy to standard PET scans. The goal was to see if this AI tool could provide a simpler, more widely available diagnostic option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mPDia clinical decision support software (device)
What this could lead to
If successful, mPDia could offer a faster, more accessible way to diagnose parkinsonism using standard MRI instead of expensive PET scans.
What could go wrong
This is a retrospective study, not a prospective trial, so real-world performance may differ. The software's accuracy depends on MRI quality and may not replace PET scans in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

221 people

The number who actually took part.

Started

Mar 2020

Finished

Oct 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

(1) Adults over 19 years old (2) 3T nigrosome 1 MRI acquired (3) 18F FP-CIT PET/CT are confirmed to be normal(normal cohort) or abnormal(abnormal cohort)

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria(Normal cohort): * Adults over 19 years old * 3T nigrosome 1 MRI acquired * 18F FP-CIT PET/CT are confirmed to be normal * The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism Inclusion Criteria(Abnormal cohort): * Adults over 19 years old * 3T nigrosome 1 MRI acquired * 18F FP-CIT PET/CT are confirmed to be abnormal * The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism Exclusion Criteria: * Patients with other brain diseases except parkinsonism * Who have anatomical abnormality in MRIs etc. * Who have other causes of tremor(e.g., thyroid disease) * Patients with lesion in basal ganglia(e.g., vascular parkinsonism, hydrocephalus and Wilson's disease)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diagnoses disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease parkinsonian disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diagnoses disease

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Catholic University of Korea, Seoul ST. Mary's Hospital

    Seoul, South Korea

  • Cha Medical Center

    Gyeonggi-do, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Gangnam Severance Hospital

    Seoul, South Korea

  • Hallym University Dongtan Sacred Heart Hospital

    Gyeonggi-do, South Korea

  • Hallym University Sacred Heart Hospital

    Gyeonggi-do, South Korea

  • Korea University Ansan Hospital

    Gyeonggi-do, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • KyungHee University Medical Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.